Reassessing a Familiar Drug: The Evidence Behind Azithromycin's Renewed Role Amid a Worsening Resistance Crisis

For much of the past decade, azithromycin occupied an uncomfortable position in clinical practice: simultaneously ubiquitous and under scrutiny. Concerns over macrolide resistance, cardiac safety signals, and pandemic-era misuse contributed to a professional climate in which the drug was increasingly regarded as a relic of easier prescribing times. Yet as 2024 draws attention to a deepening antimicrobial resistance crisis across the United States, a quieter reassessment is underway. Infectious disease specialists, pulmonologists, and primary care clinicians alike are returning to azithromycin—not out of convenience, but out of necessity, and with considerably more precision than before.

Understanding what is driving this reconsideration, and where the evidence actually supports it, is essential for any clinician who writes antibiotic prescriptions today.

The Resistance Backdrop That Changed the Calculus

The Centers for Disease Control and Prevention's most recent antimicrobial resistance threat reports paint a sobering picture. Resistance rates among common respiratory and urogenital pathogens continue to climb, particularly for fluoroquinolones and, in some geographic pockets, extended-spectrum beta-lactamase-producing organisms. When first- and second-line agents fail or are contraindicated, clinicians are compelled to revisit the broader pharmacopoeia—and azithromycin, with its unique pharmacokinetic profile and established tissue penetration, re-enters the conversation.

This is not a rehabilitation born of nostalgia. It is a pragmatic response to a shrinking formulary of reliable options. The question is not whether azithromycin deserves a second look; the evidence suggests it does in specific contexts. The more important question is whether clinicians will approach that second look with the rigor the moment demands.

Where the Data Supports Reintegration

Community-Acquired Pneumonia in Appropriate Candidates

Among patients with community-acquired pneumonia (CAP) who lack significant comorbidities, recent observational data and updated IDSA guidance continue to support azithromycin-based regimens—particularly when atypical organisms such as Mycoplasma pneumoniae or Chlamydophila pneumoniae are suspected. In outpatient settings where macrolide resistance rates remain below regional thresholds considered clinically meaningful (generally below 25%), azithromycin monotherapy retains a role. Clinicians practicing in regions with higher resistance prevalence, however, should consult local antibiograms before defaulting to this approach.

Pertussis and Select Respiratory Tract Infections

Azithromycin remains the preferred agent for Bordetella pertussis infection across all age groups in the United States, a designation that has not changed despite broader macrolide scrutiny. Its five-day dosing convenience and well-characterized pharmacodynamics make it particularly suitable in pediatric and elderly populations where treatment adherence is a practical concern. Similarly, in exacerbations of chronic obstructive pulmonary disease (COPD) where bacterial etiology is confirmed or strongly suspected, azithromycin continues to demonstrate clinical utility—both as acute treatment and, in select high-exacerbation-risk patients, as prophylactic long-term therapy under specialist guidance.

Sexually Transmitted Infections: A More Complicated Picture

The STI landscape offers a more nuanced case study. Azithromycin's role in treating Chlamydia trachomatis has been narrowed by updated CDC STI Treatment Guidelines, which now favor doxycycline as first-line therapy due to emerging resistance data and superior microbiological cure rates. However, azithromycin retains a place in pregnancy-related chlamydial infection when doxycycline is contraindicated, and in select gonorrhea combination regimens where ceftriaxone alone may be insufficient. These are not broad endorsements—they are targeted applications requiring careful clinical judgment.

Where Overuse Persists and Why It Matters

Despite the legitimate cases for azithromycin's reintegration, overuse remains a documented and consequential problem. Prescribing rates for azithromycin in acute sinusitis, upper respiratory tract infections, and bronchitis—conditions that are predominantly viral in etiology—remain disproportionately high in US ambulatory care settings. A 2023 analysis of outpatient antibiotic prescribing data found that macrolides, including azithromycin, were among the most commonly prescribed antibiotics for diagnoses where bacterial causation was either unlikely or unconfirmed.

This matters for two reasons that compound each other. First, unnecessary azithromycin exposure accelerates macrolide resistance at the population level, eroding the drug's utility in precisely the contexts where it is genuinely needed. Second, it exposes individual patients to avoidable adverse effects—including QT prolongation, gastrointestinal disturbance, and hepatotoxicity—without commensurate clinical benefit. Stewardship, in this context, is not merely an administrative principle. It is a clinical obligation.

A Framework for Evidence-Based Decision-Making

Clinicians navigating azithromycin prescribing decisions in 2024 benefit from a structured approach rather than reflex prescribing in either direction. Several practical considerations warrant attention:

• Consult local resistance data. National resistance trends inform general guidance, but local antibiograms from regional hospital networks and public health departments provide the most actionable intelligence for community prescribing.

• Clarify the indication before writing the script. Azithromycin's reemergence in certain protocols does not constitute a general license for empiric use. Confirmed or strongly suspected bacterial infection with a plausible susceptible pathogen remains the appropriate threshold.

• Account for patient-specific risk factors. Cardiac history, concurrent QT-prolonging medications, hepatic impairment, and drug-drug interaction profiles all affect whether azithromycin is the appropriate choice for a given patient—independent of whether it is the appropriate choice for the diagnosis.

• Document the clinical rationale. In an era of increasing scrutiny over antibiotic prescribing patterns, contemporaneous documentation of the evidence base for azithromycin selection supports both patient safety and professional accountability.

The Broader Stewardship Imperative

The renewed interest in azithromycin should not be mistaken for a return to the permissive prescribing culture that contributed to the resistance crisis in the first place. Rather, it reflects the kind of nuanced, evidence-calibrated decision-making that effective antibiotic stewardship demands. As resistance continues to foreclose therapeutic options across multiple drug classes, every antibiotic—including azithromycin—must be treated as a finite resource whose preservation depends on judicious use.

For clinicians, this means resisting both the overcorrection of reflexive avoidance and the complacency of habitual prescribing. Azithromycin's pharmacological profile, when matched to the right patient and the right pathogen, remains clinically valuable. The task is ensuring that prescribing decisions are driven by data rather than familiarity, and by patient need rather than convenience.

In a resistance landscape that leaves little margin for error, that distinction is not academic. It is foundational.